x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

37:46

105. ASCO 2024 - Metastatic Non Small Cell Lung Cancer

Oncology for the Inquisitive Mind ·

2024/06/03

"Tell me, Muse, the story of that resourceful man who was driven to wander far and wide after he had sacked Troy. He saw the cities of many people and he learnt their ways. Tell us this story, goddess daughter of Zeus, beginning at whatever point you will." So begins Homer's epic The Odyssey, the story of the titular hero Odysseus' long, long, LONG journey from the ruins of Troy to his home of Ithaca. Just as Odysseus set out from Troy, so do Michael and Josh begin an "odyssey" of their own. The

en

25:54

104. Metastatic Gastric and GOJ Cancer

Oncology for the Inquisitive Mind ·

2024/06/01

With ASCO upon us, Michael and Josh squeeze one more episode of their regular schedule to bring you an important update on gastric cancer. For context, the 5 year survival rate for metastatic gastric cancer is 6%, similar to that of pancreatic cancer. Despite improvement in survival due to the addition of nivolumab to chemotherapy (Checkmate 64), few therapies have significantly changed it's overall prognosis.This week Michael and Josh explore the addition of a LAG-3 inhibitor (relatlimab) to the

en

30:38

103. Metastatic Colorectal Cancer

Oncology for the Inquisitive Mind ·

2024/05/25

Oncology research never sits still, nor does the desire for better treatment options for metastatic colorectal cancer. Fifty percent of diagnosed cases develop metastatic spread during their disease course. This week, we look for the "SUNLIGHT" and investigate the combination of Lonsurf with Bevacizumab and using Fruquintinib with refractory metastatic colorectal cancer.Links to articles discussed in this episode (subscription may be required): FRESCO-2: Link SUNLIGHT: LinkFor more episodes,

en

33:24

102. Hepatocellular Carcinoma

Oncology for the Inquisitive Mind ·

2024/05/18

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian countries, predominantly due to high rates of endemic hepatitis infections.This week, we climb a mountain in search of treatment options and advancements in this orphan cancer. Two trials are discussed: The first is HIMALAYA comparing durvalumab and tremelimumab versus the old incumbent sorafenib

en

15:43

Oncosnacks 14: Bevacizumab Toxicity (Part 1)

Oncology for the Inquisitive Mind ·

2024/05/14

In many parts of the world, Bevacizumab is an important component of the treatment of glioblastoma, colorectal, hepatocellular and ovarian cancers. However, with such widespread use inevitably comes toxicity. Side effects related to bevacizumab are not your garden-variety chemotherapy side effects, nor are they similar to toxicity from immunotherapy. Rather, they stand apart, unique amongst our systemic therapies.In their latest Onconack, Josh and Michael take a look at two of the most commonly

en

33:38

101. Castration-Resistant Prostate Cancer Update

Oncology for the Inquisitive Mind ·

2024/05/11

As many philosophers have noted, life often travels in cycles. Almost two years and more than 100 episodes ago, on a virtual call far far away, two young oncologists started on a journey to bring the latest oncology evidence to anyone with ears and the will to listen. Now, for episode number 101, Josh and Michael return to where it all started: prostate cancer. Much has changed in the (nearly) two years since that episode, and so in this episode, our hosts provide an update on two more recent

en

28:19

100. 100th Episode Bonanza

Oncology for the Inquisitive Mind ·

2024/05/04

For 100 episodes, Josh and Michael have brought to your ears the latest and greatest in oncology research and treatment. In this episode, we will take a trip down memory lane, speaking about our journey up to this point, our favourite guests and favourite trials, and give you a glimpse of what the future holds for Oncology for the Inquisitive Mind. If we're honest, we never expected to get this far, and we have you, our wonderful audience to thank for that. We are so grateful for your support, you

en

33:48

99. Early Mutation-Driver Positive NSCLC

Oncology for the Inquisitive Mind ·

2024/04/27

In this episode, Josh and Michael examine the rapidly developing world of early lung cancer treatment. An area that will hopefully only grow in importance, treatment for early NSCLC is becoming ever more sophisticated, with recent developments in neoadjuvant management and confirmation of the benefit of adjuvant driver-mutation inhibitior treatment. Today's articles cover two such topics: will osimertinib finally reach the pinnacle it was born to reach and be used in the neoadjuvant treatment of

en

57:55

98. Breast Cancer with Dr Adam Brufsky

Oncology for the Inquisitive Mind ·

2024/04/20

On this very special episode, Josh and Michael welcome Dr Adam Brufsky, a trailblazer in the world of breast cancer treatment and a titan in the frenetic development of breast cancer therapies since the mid-late 90s. Dr Brufsky is a Professor of Medicine at the University of Pittsburgh School of Medicine, Chief of the university's Division of Haematology and Oncology and co-director of its Comprehensive Cancer Centre. He received his MD and PhD from the University of Connecticut's School of Medicine

en

16:50

Fireside Chats 3: Colorectal Cancer in Young People

Oncology for the Inquisitive Mind ·

2024/04/13

On today's blessedly brief episode, Josh and Michael give an overview of one of the greatest challenges for any practicing oncologist: the conundrum of cancer in young people. In recent decades, the number and proportion of young patients diagnosed with colorectal cancer has skyrocketed. This trend has been noted in news outlets across the world, reported in sources as disparate as the New York Times and the Australian Broadcasting Company. From the medical to the logistical and emotional, managing

en

9:19

Oncosnacks 13: Pancreatic Cancer - NAPOLI-3 Trial Update

Oncology for the Inquisitive Mind ·

2024/04/09

IN BREAKING NEWS... Or not really, as we are a bit late to the party. But in honour of liposomal irinotecan's recent approval by the Federal Drugs Administration, we thought we would take another look at the NAPOLI-3 trial. The first potentially practice-changing update to the treatment of advanced pancreatic cancer arguably in more than a decade, the combination of liposomal irinotecan with 5-fluorouracil and oxaliplatin proved itself superior (spoiler alert) to the established combination of

en

25:46

97. Spotlight: Which CDK4/6 Inhibitor is Best?

Oncology for the Inquisitive Mind ·

2024/04/06

It is a tale as old as time, as old as the stars, the heavens and human consciousness itself. Okay, we're exaggerating a bit, but for as long as pharmacology and capitalism have been joined at the hip, the question of "which drug is best" has been at or near the forefront of medical decision-making. With the development of standardised clinical trials and the difficulty of conducting direct head-to-head comparisons, this question has become more difficult to answer conclusively. Nowhere is this

en

39:52

96. Second Line Treatment of Melanoma

Oncology for the Inquisitive Mind ·

2024/03/30

In this episode, Michael and Josh welcome a very special guest: Michael's Labrador Beans. Beans is a world-renowned expert in eating snacks, but unfortunately, had very little to offer on their topic today: the treatment of progressive or recurrent cutaneous melanoma with primary and secondary resistance to immunotherapy. So, unfortunately, the discussion was left to your regular hosts. For approximately 50% of patients, this is fortunately not a question they need to worry about, as immunotherapy

en

24:26

95. ASCO GU 2024 Spectacular (Part 2)

Oncology for the Inquisitive Mind ·

2024/03/23

While Josh and Michael enjoy a good rambling, meandering podcast as much as the next guy, we made a promise to keep our coverage of the ASCO GU 2024 conference short and sweet. So, as promised, here is the second - and final - episode of our miniseries. For a change of pace, one of our studies involves the adjuvant use of immunotherapy! Specifically, AMBASSADOR looks at pembrolizumab in patients with early urothelial cancer, a patient cohort that is crying out for more effective treatments for

en

30:52

94. ASCO GU Part 1

Oncology for the Inquisitive Mind ·

2024/03/16

With Josh's Grand Adventure(TM) now in the books, he and Michael return to their usual programming, examining two studies presented at the not-so-recent ASCO GU conference in San Fransisco. While the conference took place in January of this year, as the old adage goes: better late than never. In this episode, our hosts examine two studies; the CONTACT-02 study examining a combination of immunotherapy + cabozantinib in patients with metastatic castration-resistant prostate cancer, and an update from

en

32:06

93. On the Road with Prof. Elgene Lim

Oncology for the Inquisitive Mind ·

2024/03/09

In this episode, Josh interviews the man who helped make this grand adventure possible, his mentor, Professor Elgene Lim of the Kinghorn Cancer Centre in Sydney. Professor Lim is a medical oncologist specialising in breast cancer research. He has previously worked at the Walter and Eliza Hall Institute, completing his PhD under the mentorship of Dr Geoffrey Lindeman and Dr Jane Visvader with research focussed on identifying culprit cells in BRCA1 mutant gene carriers. He subsequently worked with Dr

en

30:17

92. On the Road with Dr. Robert Mayer

Oncology for the Inquisitive Mind ·

2024/03/02

In this episode, Josh interviews Dr Robert Mayer, Professor of Medicine at Harvard Medical School, former director of the Dana Farber Cancer Institute’s Oncology Fellowship Program for 36 years and an expert in gastrointestinal cancer. He founded the Centre for Gastrointestinal Oncology at Dana Farber and has previously chaired the Gastrointestinal Cancer Committee of the Cancer and Leukemia Group B. Dr Mayer has also been an associate editor for both the New England Journal of Medicine and the

en

43:31

91. On the Road with Dr. Ann Partridge

Oncology for the Inquisitive Mind ·

2024/02/24

In this episode, Josh interviewed Dr Ann Partridge, the director of the adult survivorship program at the Dana-Farber Institute. She is the co-founder and director of the Program for Young Women with Breast Cancer and is passionate about communication, risk perception and behavioural aspects of cancer care. Dr Partridge is the principal investigator for the Young Women’s Breast Cancer study, which has currently enrolled over 1300 women throughout the United States, and has chaired both ASCO’s

en

58:11

90. On the Road with Dr. Harold J Burstein

Oncology for the Inquisitive Mind ·

2024/02/17

In this episode, Josh interviews Dr Harold Burstein. A graduate of Harvard University and Harvard Medical School, Dr Burstein’s initial PhD was in cellular immunology. After receiving his oncology fellowship at the Dana Farber Cancer Institute, he joined the staff in 1999. Hal has a particular interest in breast cancer and has participated in national and international clinical trials while also working to develop treatment guidelines worldwide. A passionate educator, Dr. Burstein teaches medical

en

31:51

89. Spotlight - Biotech: Interview with Dr Jeff Jones...

Oncology for the Inquisitive Mind ·

2024/02/13

Today, on this mid-week special, Oncology for the Inquisitive Mind is delighted to welcome Dr. Jeff Jones, a haematologist, oncologist and the Chief Medical Officer of Cullinan Oncology. Biotech companies are at the forefront of novel drug development, and it is fascinating to take a look behind the curtain and glimpse a small part of how targets are chosen and developed. This includes areas of unmet need, including Exon 20 EGFR mutant lung cancer treatment.Cullinan Oncology conducts research

en

202 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown